AIS
TEVA icon

Advocate Investing Services’s Teva Pharmaceuticals TEVA Stock Holding History

Advocate Investing Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.6K Hold
1,700
– – 0.04% 158
2026
Q1 		$51.2K Hold
1,700
– – 0.04% 150
2025
Q4 		$53.1K Buy
+1,700
New +$41.9K 0.05% 141

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Advocate Investing Services's TEVA Position: Q2 2026 in Review

Advocate Investing Services held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 1,700 shares worth $57.6K. The position accounts for 0.04% of the portfolio, ranked #158.

Advocate Investing Services first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Advocate Investing Services held 1,700 shares of Teva Pharmaceuticals worth $57.6K as of Q2 2026.
  • Advocate Investing Services left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up 0.04% of Advocate Investing Services's portfolio in Q2 2026, its #158 holding.
  • Advocate Investing Services first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Advocate Investing Services's 13F filing for Q2 2026, filed 29 Jul 2026.